A

Anthropic

Builds Claude AI models with a focus on safety

Healthcare and Life Sciences Sales Manager

Full-Time
$450k - $550k/yr
Expert
Bachelor's
Boston, MA, USA+2 moreMore locations: San Francisco, CA, USA | New York, NY, USA
HybridStaff are expected to work from an office at least 25% of the time.
Sales & Account ManagementAccount Executive
H1B Sponsorship Available

About the job

Requirements
  • At least 10 years of experience in healthcare and/or life sciences, including at least 5 years specifically across payor, provider, or biopharma segments, or related consulting.
  • Experience in leadership roles managing or coaching enterprise sales teams, with a record of driving measurable revenue outcomes in healthcare and/or life sciences.
  • Deep understanding of business models, operations, and economics in at least one of biopharma, payor, or provider segments, including CMS regulations, HIPAA, FDA, and competitive dynamics.
  • Experience managing or overseeing complex, multi-stakeholder sales cycles within healthcare or life sciences organizations and securing strategic deals by understanding technical requirements and clinical, administrative, or commercial use cases.
  • A record of exceeding revenue targets by managing a team's pipeline and an evolving sales process.
  • Ability to present to healthcare and life sciences audiences, including clinicians, researchers, C-suite executives, and payor leadership.
  • Genuine interest in responsible AI deployment and motivation to advance safe, beneficial AI.
  • A bachelor's degree or equivalent combination of education, training, and/or experience; relevant field knowledge may be demonstrated through coursework, training, or professional experience.
Responsibilities
  • Build and lead a specialized team of Strategic Account Executives covering biopharma, payor, and provider accounts; set growth targets by sub-segment and coach representatives through the sales cycle from outbound prospecting to close.
  • Design and oversee sales strategies tailored to sub-segment procurement cycles, translating market and trend analysis into account plans and campaigns that meet and exceed team revenue targets.
  • Identify and prioritize high-potential opportunities across clinical departments, care management teams, claims processing units, drug discovery and commercial functions, and administrative offices; partner cross-functionally to differentiate the offering for healthcare delivery, payor, and life sciences use cases.
  • Run a disciplined pipeline and forecasting cadence across the team, managing the sales process to deliver predictable performance against quota.
  • Serve as the domain expert across the healthcare and life sciences value chain, including payer operations such as claims adjudication, prior authorization, and risk adjustment; provider operations; and biopharma research and development and commercial functions. Translate that expertise into scalable playbooks, frameworks, and go-to-market strategies.
  • Partner with C-suite executives across biopharma, payor, and provider organizations to design multi-year AI transformation roadmaps and build trusted-advisor relationships.
  • Partner with Product and Applied AI to translate feedback from clinicians, care coordinators, researchers, and administrative leaders into product and roadmap input.
  • Build strategic relationships with healthcare- and life sciences-focused system integrators, health technology vendors, and industry organizations to scale go-to-market capabilities.
  • Establish the company’s position as an AI partner across healthcare and life sciences through conference presentations, white papers, case studies, and participation in industry forums.
  • Codify learnings into playbooks, templates, and best practices, partnering with Marketing and Enablement to scale winning use cases and proof points across biopharma, payor, and provider accounts.
Desired Qualifications
  • Deep understanding of buying cycles, decision-making processes, and key pain points across two or more of biopharma, payor, and provider organizations.
  • A strategic, analytical approach to assessing the healthcare and life sciences market, paired with tactical execution to capture opportunities and willingness to work directly on deals alongside the team.
  • Experience developing and refining AI use cases with customers and channel partners across care delivery, population health, administrative efficiency, drug discovery, or commercial life sciences functions.
  • Experience building or scaling a specialized sales team from an early stage.
  • Passion for or experience with advanced AI systems and their applications in clinical and life sciences settings, with conviction around safe, ethical AI development.

About the company

Anthropic builds the Claude family of AI models and sells them to businesses, software developers, and consumers, with research on making AI safe and understandable at the center of its work. In 2024 it introduced the Model Context Protocol, an open standard for connecting AI assistants to outside apps and data that OpenAI and Google adopted the next year. People use the Claude app to write and analyze files, programmers hand coding tasks to Claude Code, and companies build Claude into their own products through its API. Anthropic earns money from subscriptions, business plans, and usage-based API fees. Siblings Dario and Daniela Amodei founded Anthropic in 2021 with other former OpenAI employees, and it is based in San Francisco.

Company Size

5,001-10,000

Company Stage

N/A

Total Funding

$224.8B

Headquarters

San Francisco, California

Founded

2021

Get referred to Anthropic

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Sales are multiplying: Anthropic's yearly revenue pace topped $65 billion in July 2026, over sevenfold since December 2025.
  • IPO plans advanced: October 2026 reports describe investor meetings and a mid-November listing target; staff shares face lockups.
  • Lower office minimum: 627 of 646 Anthropic job posts in October 2026 require at least 25% office time.

What critics are saying

  • Job security rides on growth: Anthropic's IPO prospectus lists $518 billion in cloud and computing bills due in coming years.
  • Defense work stays off-limits: in September 2026, appeals judges voted 2-1 to let the Pentagon keep blacklisting Anthropic.
  • Growth is priced in: Anthropic's valuation reached $965 billion in May 2026, up from $380 billion in February.

What makes Anthropic unique

  • Investors don't control its board alone: Anthropic's independent Long-Term Benefit Trust elects a growing number of directors.
  • It isn't tied to one chipmaker: Claude runs on Nvidia GPUs plus custom AI chips designed by Google and Amazon.
  • It holds back its riskiest model: Claude Mythos 5.1, launched September 2026, goes only to vetted cyberdefenders and life scientists.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Flexible Work Hours
  • Paid Vacation
  • Parental Leave
  • Hybrid Work Options
  • Company Equity

Growth & Insights and Company News

Headcount

6 month growth

-3%

1 year growth

2%

2 year growth

-3%
Crypto Briefing
Oct 18th, 2026
Anthropic pledges 5% of shares to fund tackling AI job disruption

Anthropic, the AI company behind the Claude models, has committed 5% of its shares to a new public benefit fund that will address job disruption caused by AI. The commitment is subject to stockholder approval. The company's board could add 2% of shares for every 50% increase in Anthropic's value, at its discretion. The move builds on an earlier $200 million commitment to study and reduce AI's impact on employment.

Tech in Asia
Oct 17th, 2026
Anthropic leases Nova Scotia data center capacity in first Canada deal, tied to $7.3B EverWind project

Anthropic has signed a lease with EverWind for data center capacity at Point Tupper, Nova Scotia. It is the company's first such agreement in Canada, said Jacob Glick, Anthropic's Canada public policy head. EverWind, a Canadian developer of green energy projects, plans to invest more than C$10 billion ($7.05 billion) in the data center campus and related wind power projects. It has promoted the Cape Breton port area as a future clean fuel hub. Glick said Anthropic would protect ratepayers and water resources while ensuring local communities benefit.

TechCrunch
Oct 16th, 2026
Replit drops Anthropic for OpenAI over cost and performance, CEO says

Replit is no longer working with Anthropic, chief executive officer and co-founder Amjad Masad said Thursday at TechCrunch Disrupt. He cited cost, partnership and performance. "I think ChatGPT is better now," Masad said, adding that Replit's internal and public benchmarks show Sol and Astra build vibe-coded applications from scratch more effectively. Replit announced a partnership with OpenAI in August. An unnamed person familiar with the matter said the Anthropic partnership was still in place. A September blog post cited Anthropic's Claude models as running in Replit Agent's production environment. Masad said enterprise contracts made up about 15% of revenue this year, up from 2% last year. More than 50% of revenue is B2B.

Yahoo Finance
Oct 16th, 2026
Anthropic gets top junk credit rating from KBRA ahead of $35B chip financing

Anthropic received a double B plus issuer rating from Kroll Bond Rating Agency (KBRA) in June, the highest speculative-grade score and one notch below investment grade. The rating came before a $35bn chip financing led by Apollo, according to documents seen by the FT. Investment grade would lower the AI startup's borrowing costs and open it to investors such as pension funds and life insurers. Anthropic expects to spend more than $500bn on computing and infrastructure over the next decade. KBRA used a "risk score" because Anthropic withheld metrics including free cash flow. About $4.4bn of junior debt in the package carries Anthropic's credit risk and was sold at a yield of about 8.5%. Banks are now assembling a $60bn deal for more custom AI chips.

Yahoo Finance
Oct 15th, 2026
Claude's AI portfolio puts 14.5% in EMCOR as data centre demand lifts revenue 19.7%

Claude's AI stock portfolio holds 14.5% of its assets in EMCOR Group (NYSE:EME), its largest position. The portfolio is up 28.4% since late November 2025, against 15.3% for the S&P 500, according to the investing app Rallies. EMCOR installs power systems, backup generators, and cooling networks for data centres. Revenue rose 19.7% in the first quarter of 2026, with organic growth of 16.8%. The stock trades at a forward P/E of 24, against 19.1 for the S&P 500. Analysts expect earnings per share to rise 27% in 2026 and about 12% in 2027. Risks include order pauses, cost overruns, and slowing growth. The dividend yield is just 0.18%.